Q2 Earnings Forecast for VRDN Issued By B. Riley

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Equities research analysts at B. Riley issued their Q2 2025 EPS estimates for shares of Viridian Therapeutics in a report issued on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will post earnings of ($1.14) per share for the quarter. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The company had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.05 million.

Other equities research analysts have also issued reports about the stock. Wells Fargo & Company reiterated an “equal weight” rating and set a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. TD Cowen began coverage on shares of Viridian Therapeutics in a report on Monday, November 25th. They issued a “buy” rating for the company. Needham & Company LLC restated a “buy” rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th. HC Wainwright restated a “buy” rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a report on Monday, December 16th. Finally, Royal Bank of Canada upped their price objective on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $35.70.

Viridian Therapeutics Trading Down 7.2 %

NASDAQ:VRDN opened at $14.41 on Tuesday. The company has a fifty day moving average of $18.10 and a 200 day moving average of $19.70. Viridian Therapeutics has a 52 week low of $11.40 and a 52 week high of $27.20. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.14 billion, a P/E ratio of -3.34 and a beta of 1.32.

Institutional Trading of Viridian Therapeutics

Several institutional investors have recently bought and sold shares of VRDN. R Squared Ltd purchased a new stake in shares of Viridian Therapeutics during the 4th quarter valued at about $26,000. Foresite Capital Management VI LLC purchased a new stake in shares of Viridian Therapeutics during the 4th quarter valued at about $38,000. AlphaQuest LLC boosted its holdings in shares of Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after acquiring an additional 1,519 shares during the last quarter. Summit Investment Advisors Inc. boosted its holdings in shares of Viridian Therapeutics by 24.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock valued at $147,000 after acquiring an additional 1,516 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Viridian Therapeutics during the 3rd quarter valued at about $149,000.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.